solute carrier family 14 member 2Genealiases: HUT2 · UT-A2 · UT2 · UTA · UTR · hUT-A6
Q-omics provides the consensus-scored SLC14A2 profile across patient tissues and cancer cell-line models. SLC14A2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SLC14A2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SLC14A2 RNA expression shows 14,382 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight LUAD, KIRC, and PAAD as cancer lineages where SLC14A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC14A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC14A2 survival associations across molecular data types. SLC14A2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC14A2 RNA expression–survival associations across cancer types. High SLC14A2 expression shows unfavorable associations in KIRP and KIRC, but favorable associations in LUAD, MESO, SKCM and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SLC14A2 RNA expression.
This table summarizes SLC14A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC14A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC14A2 shows lower tumor expression in KIRC, KIRP, BRCA, LUSC, KICH and THCA. The KIRC box plot shows higher SLC14A2 RNA expression in normal versus tumor tissue (log2 FC = −2.874, t-test p < 0.001).
This table shows molecular features associated with SLC14A2 in patient tissues and cancer cell lines. In patient samples, SLC14A2 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC14A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
